PolyPid_logo.jpg
PolyPid Provides Corporate Update and Reports Second Quarter 2022 Financial Results
August 10, 2022 07:00 ET | PolyPid Ltd.
Signed Exclusive Licensing Agreement for Commercialization of D-PLEX100 in Europe for Potentially Over $110 Million in Upfront and Milestone Payments, Plus Royalties on Net SalesIndependent Data...
PolyPid_logo.jpg
PolyPid Announces Exclusive Licensing Agreement with ADVANZ PHARMA for the Commercialization of D-PLEX₁₀₀ in Europe
August 03, 2022 07:00 ET | PolyPid Ltd.
PolyPid to potentially receive over $110 million in upfront and milestone payments as well as royalties on net sales ADVANZ PHARMA to receive exclusive rights to commercialize D-PLEX100 for the...
PolyPid_logo.jpg
PolyPid to Report Second Quarter 2022 Financial Results and Operational Highlights on August 10, 2022
July 27, 2022 07:00 ET | PolyPid Ltd.
PETACH TIKVA, Israel, July 27, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today...
PolyPid_logo.jpg
PolyPid Announces Presentation of Phase 2 D-PLEX₁₀₀ Clinical Data at the Midwest Surgical Association 2022 Annual Meeting
July 25, 2022 07:00 ET | PolyPid Ltd.
Efficacy Data of D-PLEX100 in the Prevention of Post-Abdominal Surgery Incisional Infection in High-Risk Patients will be Presented During a Podium Presentation PETACH TIKVA, Israel, July 25,...
PolyPid_logo.jpg
PolyPid Announces Dikla Czaczkes Akselbrad Assumes Role of CEO
July 05, 2022 07:00 ET | PolyPid Ltd.
PETACH TIKVA, Israel, July 05, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, announced today...
PolyPid_logo.jpg
PolyPid Hosting Key Opinion Leader Webinar on Managing the Cost of Surgical Site Infections
June 15, 2022 07:00 ET | PolyPid Ltd.
PETACH TIKVA, Israel, June 15, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced...
PolyPid_logo.jpg
PolyPid Announces Presentation of D-PLEX₁₀₀ Phase 2 Clinical Data at ASM Microbe 2022
June 06, 2022 07:00 ET | PolyPid Ltd.
Phase 2 clinical data on the efficacy of D-PLEX100 in surgical site infection prevention in elective colorectal surgery will be presented during a poster presentation PETACH TIKVA, Israel, June 06,...
PolyPid_logo.jpg
PolyPid to Present at the JMP Securities 2022 Life Sciences Conference
June 02, 2022 07:00 ET | PolyPid Ltd.
PETACH TIKVA, Israel, June 02, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today...
PolyPid_logo.jpg
PolyPid Announces Publication of Animal Model Studies in 2022 ASCO Annual Meeting Abstract Demonstrating that Locally Administered OncoPLEX Potentially Decreases the Likelihood of Tumor Recurrence with Reduced Side Effects
June 01, 2022 07:00 ET | PolyPid Ltd.
Locally Administered Docetaxel Through Extended-Release Delivery via the Company’s PLEX Technology Offers Potentially Enhanced Adjuvant Chemotherapy Option PETACH TIKVA, Israel, June 01, 2022 ...
PolyPid_logo.jpg
PolyPid Announces Completion of Enrollment in Phase 3 SHIELD I Trial of D-PLEX₁₀₀ for Prevention of Surgical Site Infections in Abdominal Surgery
May 31, 2022 07:00 ET | PolyPid Ltd.
Following Unblinded Interim Efficacy Analysis, Data Safety Monitoring Board Recently Recommended Concluding Study at 950 Patients, the Minimum Number of Patients TargetedTop-line Results Expected by...